Because so few persons in this age group were vaccinated Cases per 2 FIGURE IV Guillain-Barre Syndrome Attack Rate for Population >17 years of age, by week of onset after A/New Jersey Influenza Vaccination United States, Oct. 1976-Jan.1977 Attributable Risk (for 1st 10 weeks = 10.3 cases per) million vaccinees Expected Based on Attack Rate for Unvaccinated 8 9 10 11 12 13 14 15 16 17 WEEK AFTER VACCINATION 2 3 4 5 6 7 .21 FIGURE V Guillain-Barre Syndrome Relative Risks for Population >17 Years of Age, Mr. ROGERS. Thank you very much, Dr. Millar. What has been the cost of the vaccine? Dr. MILLAR. The estimated final costs for the vaccine would be $67 million. Mr. ROGERS. What is it per dose? Dr. MILLAR. 37 cents per dose, or 42 cents per dose if selfinsurance retention funds are included. Mr. ROGERS. What about the bivalent vaccine, what is the cost of bivalent? Mr. BRADFORD. Mr. Chairman, they varied somewhat between manufacturers. We could provide that. Bivalent costs more than the monovalent. [The following information was received for the record:] |